Updated September 2026Four-week billing, pharmacy namedHealthSource review
Every figure is quoted per four weeks rather than per month, and the dispensing pharmacy type is stated.
The verdict
HealthSource publishes $199 every four weeks for compounded semaglutide, read August 2026, with tirzepatide at $299 and its sublingual tablet at $399 on the same interval. Each figure is the entry tier of several, and the tirzepatide line states it is dispensed through a 503A partner pharmacy.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- States
- 50
- Injection
- From $216/mo
- Oral
- From $434/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- 50 states
HealthSource sells both molecules by injection and tirzepatide as a sublingual tablet, across a stated fifty states. The semaglutide is supplied as a vial with syringes and alcohol pads, combined with B12, and the pages list several dose tiers of which the published figure is the lowest.
Who writes the prescription, and what do they see?
A prescription precedes dispensing and the pages describe the product in unusual detail — what is in the vial, what ships with it, and which class of pharmacy fills it. Naming the 503A partner is the disclosure worth noting, because the compounding source is the thing most sellers in this category leave unstated.
The billing interval is the quiet detail. Every figure is quoted every four weeks, which is thirteen charges across a year rather than twelve. HealthSource states the interval plainly on each product page rather than presenting the figure as monthly. A careful reader is therefore not misled. A reader comparing headline numbers against a monthly seller will be.
What happens when the dose goes up?
Multiple dose tiers exist on each line and the published figure is the entry one. HealthSource names the tiers: full dose, and starter blocks of four, six and eight weeks. What each costs is not published. A reader knows the ladder exists and not what climbing it involves.
What the price includes
Read the interval before the figure. $199 every four weeks is more expensive across a year than $199 a month, by roughly one extra charge. The sublingual tirzepatide at $399 is the dearest line and ships in five to ten business days, which the page states. Each figure is a floor, since dose tiers sit above it.
What it claims, and what it cites
The lines are compounded, so none has been through FDA review for safety or quality before dispensing. The semaglutide is combined with B12, a formulation the approved product does not use. The sublingual tablet is taken once daily before bed, and sublingual milligrams do not read across to injected ones.
Where it holds up, and where it does not
- Strength: The dispensing pharmacy class is named
- Strength: Billing interval stated on every page
- Strength: What ships with the vial is itemized
- Strength: Coverage stated across fifty states
- Limitation: Four-week billing means thirteen charges
- Limitation: Tier prices above the entry one are unpublished
- Limitation: Every figure is an entry-tier floor
- Limitation: B12 combination effect is not described
What the evidence says about this kind of treatment
The assessment above is about HealthSource. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants the compounding source identified and the contents itemized.
- Wrong for
- A reader comparing against monthly sellers without adjusting for the interval.
How HealthSource compares
| Seller | Who it suits | Go |
|---|---|---|
 Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | See Liberty → |
 Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | See Enhance MD → |
| KERNX Health | A reader who wants the clinician charge stated as a number before intake, and who is comparing the standard rate rather than the founding one. | See KERNX Health → |
More GLP-1 telehealth sellers reviews: ARSYNL RxAscend MedicalAVARA RxBayan HealthBetterMe RxBioGlow Health
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- Is $199 a monthly price?
- No. It is quoted every four weeks, which is thirteen charges across a year rather than twelve.
- Who compounds the medication?
- The tirzepatide line states it is dispensed through a 503A partner pharmacy. That is more than most sellers here disclose about their source.
- What do the higher tiers cost?
- Not published. HealthSource names full-dose and starter tiers of four, six and eight weeks without pricing them, so the published figure is a floor.
- Is HealthSource legit?
- HealthSource is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is HealthSource expensive compared with other GLP-1 telehealth sellers?
- HealthSource publishes a starting figure of $216/mo. Across the 83 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $179, which puts HealthSource above the median. The other 5 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.